Shanghai RAAS Blood Products terminates planning for major asset restructuring and resumes trading on January 7th.

Shanghai RAAS Blood Products (002252.SZ) announced that the company had previously planned to merge with Qingdao Haier Biomedical Co., Ltd. by issuing A-shares to all shareholders of Shanghai RAAS Blood Products, in order to raise funds through the issuance of A-shares. After careful consideration, the company has decided to terminate the planned transaction. The company's stock will resume trading on January 7, 2025 (Tuesday).